Revision as of 07:49, 12 January 2022

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz

Overview

The goal of Primary prevention is to prevent the occurrence of an illness or a disease before it ever occurs. In the case of bacterial pneumonia, primary prevention can be achieved by the administration of vaccination as well as attempting to control underlying comorbidities that may predispose an individual to pneumonia. When certain conditions are present, it may also be helpful to treat with prophylactic antibiotics.^[1] Educating the public as well as identifying those most susceptible to infection can help reduce the risk of pneumonia.

Vaccination

Pneumonia Main Page
	Bacterial pneumonia Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Bacterial pneumonia from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Bacterial pneumonia primary prevention On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Bacterial pneumonia primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Bacterial pneumonia primary prevention
CDC onBacterial pneumonia primary prevention
Bacterial pneumonia primary prevention in the news
Blogs on Bacterial pneumonia primary prevention
to Hospitals Treating Bacterial pneumonia
Risk calculators and risk factors for Bacterial pneumonia primary prevention

-Routinely administered vaccines include:

Pneumococcus (Intramuscular Conjugate or polysaccharide vaccine)
Annual vaccine against H. influenza(Intramusuclar killed vaccine)

Pneumococcus Vaccine Indications^[2]^[3]
	Advantages	Disadvanatges	Indications
PCV13 (Conjugate vaccine)	immune response is more effective, especially in the elderly and children under the age of 2 long-lasting immunity due to the formation of memory B cells mucosal immunity (promotes herd immunity)	protects against fewer serotypes	all babies and children younger than 2 years infants and childhood routine vaccines all adults aged 65 years or older
PPSV23 (Polysaccharide vaccine)	protects against a wider range of serotypes	antibodies decline over 5 years does not produce an immunological response in children under the age of 2	recommended for all adults over the age of 65 recommended for ages 19-64 with certain medical conditions: Chronic heart, lung, or liver diseases Diabetics Current smokers Alcoholics
PCV13 + PPSV23			All patients above the age of 65 Very high risk patients below the age of 65 Sickle cell disease and asplenia Immunocompromised patiest Chronic kidney disease CSF fluid leaks

Controlling Underlying Comorbidities and Patient Education

Conditions Requiring Prophylaxis

References

↑ https://www.cdc.gov/pneumococcal/clinicians/prevention.html. Missing or empty |title= (help)
↑ Hayward S, Thompson LA, McEachern A (2016). "Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ". J Patient Cent Res Rev. 3 (2): 111–115. doi:10.17294/2330-0698.1214. PMC 4927079. PMID 27376105.
↑ Grief SN, Loza JK (2018). "Guidelines for the Evaluation and Treatment of Pneumonia". Prim Care. 45 (3): 485–503. doi:10.1016/j.pop.2018.04.001. PMC 7112285 Check |pmc= value (help). PMID 30115336.

Template:WikiDoc Sources

[CDC-1] ttps://www.cdc.gov/pneumococcal/clinicians/prevention.html. Missing or empty |title= (help)

[pmid27376105-2] Hayward S, Thompson LA, McEachern A (2016). "Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ". J Patient Cent Res Rev. 3 (2): 111–115. doi:10.17294/2330-0698.1214. PMC 4927079. PMID 27376105.

[pmid30115336-3] Grief SN, Loza JK (2018). "Guidelines for the Evaluation and Treatment of Pneumonia". Prim Care. 45 (3): 485–503. doi:10.1016/j.pop.2018.04.001. PMC 7112285 Check |pmc= value (help). PMID 30115336.

[1]

[2]

[3]

@@ Line 8: / Line 8: @@
 =Vaccination=
 -Routinely administered vaccines include:
-* Pneumococcus
-* Annual vaccine against H. influenza
-=Controlling Underlying Comorbidities=
+*Pneumococcus (Intramuscular Conjugate or  polysaccharide vaccine)
+*Annual vaccine against H. influenza(Intramusuclar killed vaccine)
-=Conditions Requiring Prophylaxis=
+{| class="wikitable"
+|+Pneumococcus Vaccine Indications<ref name="pmid27376105">{{cite journal| author=Hayward S, Thompson LA, McEachern A| title=Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ. | journal=J Patient Cent Res Rev | year= 2016 | volume= 3 | issue= 2 | pages= 111-115 | pmid=27376105 | doi=10.17294/2330-0698.1214 | pmc=4927079 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27376105  }}</ref><ref name="pmid30115336">{{cite journal| author=Grief SN, Loza JK| title=Guidelines for the Evaluation and Treatment of Pneumonia. | journal=Prim Care | year= 2018 | volume= 45 | issue= 3 | pages= 485-503 | pmid=30115336 | doi=10.1016/j.pop.2018.04.001 | pmc=7112285 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30115336  }}</ref>
+!
+!Advantages
+!Disadvanatges
+!Indications
+|-
+|'''PCV13 (Conjugate vaccine)'''
+|
+* immune response is more effective, especially in the elderly and children under the age of 2
+* long-lasting immunity due to the formation of memory B cells
+* mucosal immunity (promotes herd immunity)
+|
+* protects against fewer serotypes
+|
+* all babies and children younger than 2 years
+* infants and childhood routine vaccines
+* all adults aged 65 years or older
+|-
+|'''PPSV23 (Polysaccharide vaccine''')
+|
+* protects against a wider range of serotypes
+|
+* antibodies decline over 5 years
+* does not produce an immunological response in children under the age of 2
+|
+* recommended for all adults over the age of 65
+* recommended for ages 19-64 with certain medical conditions:
+# Chronic heart, lung, or liver diseases
+# Diabetics
+# Current smokers
+# Alcoholics
+|-
+|'''PCV13 + PPSV23'''
+|
+|
+|
+* All patients above the age of 65
+* Very high risk patients below the age of 65
+# Sickle cell disease and asplenia
+# Immunocompromised patiest
+# Chronic kidney disease
+# CSF fluid leaks
-=Patient Education=
+<br />
+|}
-==References==
+=Controlling Underlying Comorbidities and Patient Education=
+<br />
+=Conditions Requiring Prophylaxis=
+<br />
+=References=
 {{Reflist|2}}

Bacterial pneumonia primary prevention: Difference between revisions

Revision as of 07:49, 12 January 2022

Overview

Vaccination

Controlling Underlying Comorbidities and Patient Education

Conditions Requiring Prophylaxis

References

Navigation menu

Bacterial pneumonia primary prevention: Difference between revisions

Revision as of 07:49, 12 January 2022

Overview

Vaccination

Controlling Underlying Comorbidities and Patient Education

Conditions Requiring Prophylaxis

References

Navigation menu

Search